Traws Pharma, Inc.
TRAW · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 0.01 | 0.04 |
| FCF Yield | -69.40% | -47.32% | -108.57% | -28.12% |
| EV / EBITDA | 1.79 | 1.51 | 1.50 | 0.55 |
| Quality | ||||
| ROIC | -15.10% | -63.56% | -59.39% | -70.94% |
| Gross Margin | 100.00% | 96.49% | 100.00% | 96.46% |
| Cash Conversion Ratio | 9.57 | -0.05 | 0.08 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 89.19% | -48.02% | -45.72% | -49.02% |
| Free Cash Flow Growth | -48.00% | 58.99% | -122.39% | 1.34% |
| Safety | ||||
| Net Debt / EBITDA | 5.24 | 2.52 | 3.24 | 2.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 43.57 | -365,583.16 | 28.93 | -94,463.16 |